Key result
Oral administration of sodium thiosulfate lowered systolic and diastolic blood pressure by 7 and 9 mm Hg, respectively, in rats with adenine-induced chronic kidney disease.
Why the study?
Hypertension is highly prevalent in CKD, and it was unknown whether oral sodium thiosulfate, an H2S-based therapy, exerts a protective effect against hypertension in CKD.
Does oral administration of sodium thiosulfate improve hypertension in an adenine-induced CKD rat model?
Does oral administration of sodium thiosulfate improve hypertension in an adenine-induced CKD rat model?
Mean Difference: -7
Absolute Event Rate: 138% vs 145%
p-value: p=<0.05
Oral administration of sodium thiosulfate lowers blood pressure in a rat model of CKD-induced hypertension, suggesting potential for H2S-targeting therapies.
Hypertension is highly prevalent in chronic kidney disease (CKD). Hydrogen sulfide (H2S) is an endogenously produced gasotransmitter with vasodilator properties. We, hence, investigated whether oral administration of sodium thiosulfate (STS), a clinically applicable H2S-based therapy, can exert a protective effect against hypertension in an adenine-induced CKD rat model. Eight-week-old male Sprague–Dawley rats were fed with 0.5% adenine chow for 3 weeks to induce CKD. After 1 week, the rats were divided into two groups: one without and one with STS (2 g/kg body weight/day) in drinking water for 2 weeks. Treatment with STS lowered systolic and diastolic blood pressure by 7 and 9 mm Hg, respectively. Renal H2S-generating enzyme expression was inhibited by CKD, while STS therapy increased plasma levels of H2S and thiosulfate. Additionally, restoration of nitric oxide bioavailability and rebalance of the renin–angiotensin system may contribute to the protective effects of STS. Our data suggest that the oral administration of STS improves hypertension in an adenine-induced CKD model, which brings us closer to the clinical translation of H2S-targeting therapy in CKD-induced hypertension.
No takes yet. Share an insight, caveat, or question.
Hsu et al. (2022) studied Adenine-induced chronic kidney disease and hypertension (n=32). Sodium thiosulfate vs. Adenine-induced CKD without sodium thiosulfate was evaluated on Systolic blood pressure (MD -7 mmHg, p=<0.05). Oral administration of sodium thiosulfate lowered systolic and diastolic blood pressure by 7 and 9 mm Hg, respectively, in rats with adenine-induced chronic kidney disease.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: